Company CStone Pharmaceuticals

Equities

2616

KYG2588M1006

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for CStone Pharmaceuticals

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Hong Kong S.E. Other stock markets 01:38:20 26/04/2024 pm IST			5-day change	1st Jan Change
0.9 ^HKD	0.00%		+5.88%	-60.35%

24/04	Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5%	MT
23/04	CStone Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023	CI

CStone Pharmaceuticals is a China-based investment holding company. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The Company conducts its businesses mainly in domestic market.

Number of employees: 474

HKD in Million	2022	Weight	2023	Weight	Delta
Biopharmaceutical Products 100.0 %	560	100.0 %	513	100.0 %	-8.44%

HKD in Million	2022	Weight	2023	Weight	Delta
China (excluding Hong Kong and Taiwan) 79.8 %	554	99.0 %	409	79.8 %	-26.17%
France 17.8 %	-	-	91	17.8 %	-
Others 2.3 %	6	1.0 %	12	2.3 %	+114.00%

Managers	Title	Age	Since
Jian Xin Yang CEO	Chief Executive Officer	60	01/16/01
Jun Cheng DFI	Director of Finance/CFO	44	01/22/01
Ying Hua Zhang COO	Chief Operating Officer	44	01/16/01
Wei Cong Ni SEC	Corporate Secretary	-	01/18/01
Sanhu Wang LAW	General Counsel	53	01/19/01
Shirley Zhao PRN	Corporate Officer/Principal	-	06/19/06
Michael J. Choi PRN	Corporate Officer/Principal	53	01/21/01
Yin Kwan Ho SEC	Corporate Secretary	47	28/22/28

Members of the board	Title	Age	Since
Edward Hu BRD	Director/Board Member	61	09/21/09
Wei Li BRD	Director/Board Member	52	01/18/01
Ting Yuk Wu BRD	Director/Board Member	69	14/19/14
Hong Bin Sun BRD	Director/Board Member	48	14/19/14
Paul Herbert Chew BRD	Director/Board Member	72	14/19/14
Xiang Hong Lin BRD	Director/Board Member	53	30/20/30
Jian Xin Yang CEO	Chief Executive Officer	60	01/16/01
Kenneth Hitchner BRD	Director/Board Member	63	10/21/10

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,284,191,212	671,409,282 ( 52.28 %)	0	52.28 %

Name	Equities	%	Valuation
6 Dimensions Capital 22.85 %	293,381,444	22.85 %	35 M $
Suzhou Oriza Holdings Co. Ltd. 5.883 %	75,553,730	5.883 %	9 M $
GIC Special Investments Pte Ltd. 4.627 %	59,422,472	4.627 %	7 M $
Jian Xin Yang 1.233 %	15,834,256	1.233 %	2 M $
Ning Jun Jiang 1.016 %	13,048,250	1.016 %	2 M $
Bosera Asset Management Co., Ltd. 0.7215 %	9,265,500	0.7215 %	1 M $
Kenneth Hitchner 0.2010 %	2,581,490	0.2010 %	310 063 $
Amundi Ireland Ltd. (United Kingdom) 0.0609 %	782,500	0.0609 %	93 986 $
Xinyuan Asset Management Co., Ltd. 0.0580 %	745,000	0.0580 %	89 482 $
China Asset Management (Hong Kong) Ltd. 0.005607 %	72,000	0.005607 %	8 648 $

CStone Pharmaceuticals Co. Ltd.

North Block Suzhou Industrial Park 218 Xinghu Street

200126, Shanghai

+86 512 8718 6550

http://www.cstonepharma.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.8331 CNY

Average target price

3.186 CNY

Spread / Average Target

+282.49%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
CSTONE PHARMACEUTICALS	-60.35%	146M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs